LGC Diagnostics & Genomics is attending the AACB 63rd Annual Scientific Conference.

LGC Diagnostics & Genomics delivers customer-focused scientific excellence, providing critical tools and solutions that enable confidence in data, decisions, and outcomes across the life sciences. With more than 1,500 employees, 13 sites worldwide, and a growing portfolio of over 17,000 products, the organization is a trusted partner to laboratories, developers, and researchers spanning clinical diagnostics, genomics, therapeutics, and agriculture. United by the mission Science for a Safer World, LGC Diagnostics & Genomics is committed to advancing innovation while upholding the highest standards of quality, reliability, and performance. LGC Diagnostics & Genomics brings together four complementary brands, SeraCare Clinical Diagnostics, Biosearch Technologies Oligo-Synthesis, Lucigen Reagent Components, and Rapid Genomics Genotyping Solutions, each addressing distinct yet interconnected needs across the life science value chain. Together, these brands support the full journey from discovery and development through validation, manufacturing, and real-world application, enabling customers to advance innovation while maintaining the highest standards of quality, accuracy, and scalability. LGC Diagnostics & Genomics enables customers to move from data to decision with confidence—advancing diagnostics, therapeutics, and agricultural innovation worldwide while delivering measurable impact in service of a safer, healthier future.